Stoke Therapeutics Inc
NASDAQ:STOK
Stoke Therapeutics Inc
Pre-Tax Income
Stoke Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Stoke Therapeutics Inc
NASDAQ:STOK
|
Pre-Tax Income
-$108.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$7.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Stoke Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-108.5m
USD
Based on the financial report for Mar 31, 2024, Stoke Therapeutics Inc's Pre-Tax Income amounts to -108.5m USD.
What is Stoke Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-46%
Over the last year, the Pre-Tax Income growth was -10%. The average annual Pre-Tax Income growth rates for Stoke Therapeutics Inc have been -23% over the past three years , -46% over the past five years .